文献速递瓣膜外科

美国肥厚型心肌病外科治疗现状

Contemporary Surgical Management of Hypertrophic Cardiomyopathy in the United States.
PubMed 文献 · Ann Thorac Surg · 2018-10-13

基于STS数据库2014-2017年2382例室间隔心肌切除术患者,比较单纯手术与合并二尖瓣手术的结局。单纯手术组死亡率和主要并发症更低,风险调整后合并二尖瓣手术组复合终点风险比为1.8。对重度二尖瓣反流,单纯手术与合并二尖瓣修复的缓解率相似。

要点

  • 单纯室间隔心肌切除术的死亡率和主要并发症低于合并二尖瓣手术。
  • 风险调整后,合并二尖瓣手术的复合终点风险比为1.8。
  • 对重度二尖瓣反流,单纯手术与合并二尖瓣修复的缓解率相似。

核心结论

  • 室间隔心肌切除术治疗肥厚型心肌病是安全的。
  • 单纯室间隔心肌切除术可能较合并二尖瓣修复或置换具有风险调整后的结局优势。
  • 室间隔心肌切除术与合并二尖瓣修复对二尖瓣反流的缓解程度相似。

研究设计与样本

  • 基于美国胸外科医师学会数据库的回顾性队列研究,纳入2014年7月至2017年6月间4274例室间隔心肌切除术,排除急诊、心内膜炎、主动脉瓣狭窄及计划主动脉瓣手术,最终分析2382例。
  • 单纯手术组1581例(66.4%),合并二尖瓣手术组801例(33.6%),后者再分为二尖瓣修复500例和二尖瓣置换301例。
  • 比较基线特征,并评估风险调整后的手术死亡率和主要并发症。

主要发现

  • 单纯手术组与合并二尖瓣手术组的手术死亡率为1.6%对2.8%(p=0.046),主要并发症为10.9%对20.0%(p<0.001)。
  • 对重度3-4+二尖瓣反流,单纯手术有效缓解415例中的355例(85.5%),合并二尖瓣修复有效缓解200例中的176例(88.0%),p=0.4061。
  • 风险调整后,合并二尖瓣手术组较单纯手术组复合终点(死亡和主要并发症)的优势比为1.8(95%置信区间:1.4至2.4,p<0.0001)。

临床怎么用

  • 对于适合的肥厚型梗阻性心肌病患者,单纯室间隔心肌切除术是安全且可能优于合并二尖瓣手术的选择。
  • 对合并重度二尖瓣反流者,单纯室间隔心肌切除术可有效缓解反流,与合并二尖瓣修复效果相似。

局限性

  • 需要进一步的纵向分析来明确特定病理解剖亚组的技术疗效和结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The primary surgical therapy for hypertrophic cardiomyopathy with obstruction is septal myectomy (SM). The current outcomes of SM with and without concomitant mitral operations in the United States was examined using The Society of Thoracic Surgeons database. METHODS: From July 2014 through June 2017, 4,274 SM operations were performed. Emergent status, endocarditis, aortic stenosis, and planned aortic valve operations were excluded. In the final cohort of 2,382 patients, 1,581 (66.4%) received SM alone (group 1), and 801 (33.6%) had SM with mitral valve repair or replacement (group 2). Group 2 was subdivided into mitral valve repair (MVr [n = 500]) and mitral valve replacement (MVR [n = 301]). Baseline characteristics were compared and risk-adjusted operative mortality and major morbidity were evaluated between treatment groups. RESULTS: Baseline comorbidity was lower in group 1 versus group 2 and for MVr versus MVR. Operative mortality and major morbidity was lower for group 1 versus 2 (1.6% versus 2.8%, p = 0.046, and 10.9% versus 20.0%, p < 0.001, respectively). For patients with severe 3-4+ mitral regurgitation, SM alone was effective in reducing mitral regurgitation in 85.5% (355 of 415), and SM with MVr was effective in 88.0% (176 of 200; p = 0.4061). After risk adjustment, odds ratio for composite of mortality and major morbidity for group 2 versus group 1 was 1.8 (95% confidence interval: 1.4 to 2.4, p < 0.0001). CONCLUSIONS: Septal myectomy for hypertrophic cardiomyopathy is safe. Septal myectomy alone may have risk-adjusted outcome advantages over SM with mitral valve repair or replacement. Septal myectomy and SM with MVr provide similar reduction in mitral regurgitation. Further longitudinal analyses are required to define technical efficacy and outcomes in selected pathoanatomic groups.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Wei LM, Thibault DP, Rankin JS, et al. Contemporary Surgical Management of Hypertrophic Cardiomyopathy in the United States. Ann Thorac Surg. 2018. PMID: 30326232. doi:10.1016/j.athoracsur.2018.08.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。